Clostridium difficile Ricardo A. Caicedo, M.D.. OBJECTIVES Introduction Epidemiology Clinical spectrum Diagnosis Treatment Prevention.

Slides:



Advertisements
Similar presentations
Relapsing and Severe C. difficile Disease Role of Fecal Microbiota Transfer.
Advertisements

HIGH VALUE CARE GI CONDITIONS CHRONIC DIARRHEA EDWARD LEVINE MD OSUWMC OCTOBER 11, 2014.
Clostridium Difficile Infectious Diarrhea
CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA VALERIE FLETCHER, M.D. INFECTIOUS DISEASES SOUTHERN OHIO MEDICAL CENTER August 2006.
Infectious Diarrhea. Definition Of Diarrhea Increase in stool frequency or a decreased stool consistency Usual stool fluid content: 10 ml/kg/d in an infant.
Neil Stollman MD, FACP, FACG Associate Clinical Professor of Medicine
Clostridium Difficile
Clostridium difficile Presented by Nate Smith, MD, MPH Carole Yeung, RN CIC.
Clostridium Difficile (C.diff): Fast Facts. What is Clostridium difficile (C. diff)? C. diff is a bacteria that lives in the intestinal tract of about.
DIARRHOEAL DISEASES Causes of Over-indulgence in Chemical Long-term antibiotic Viral causes: # Rotavirus # Norwalk.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Deadly Diarrhea …and the salvation of stool Teri Brentnall, M.D. Professor, Medicine Gastroenterology.
TechLab Diarrheal Diseases in Underdeveloped Countries Worldwide Problem More than 10,000 deaths per day On average, about 18 diarrheal episodes per year.
Microbe of the Week Mycobacterium marinum The aquarium or fish tank disease,first reported in 1962 Rare but important if not treated Living example-Karen.
Gram positive Cocci Staphylococci Streptococci Enterococci Bacilli Bacillus Clostridia Corynebacteria.
Giardia Lamblia. Giardia Giardia lamblia is a flagellated protozoan that infects the duodenum and small intestine. range from asymptomatic colonization.
C. Difficile and Fecal Microbiota Therapy
Clostridium difficile Colitis. C. diff.—Gram stain.
Management of Clostridium difficile Infections
Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.
1 What’s All the Fuss About Clostridium difficile? Peter C. Iwen, PhD, D(ABMM) Nebraska Public Health Laboratory
Antimicrobials and risks for antibiotic-associated diarrhea (AAD) Antibiotic-associated diarrhea 5-30% risk Higher with multiple IV drugs Higher with broad.
Probiotics Terms: Probiotic – Probiotics are live microorganisms (bacteria or yeasts) which, when administered in adequate amounts, confer a health benefit.
Microbiology of the GIT Ziad Elnasser, MD, Ph.D. Amebiasis Entamoeba histolytica. Entamoeba histolytica. Acute and chronic diarrheas. Acute and chronic.
MICR 420 Emerging and Re-Emerging Infectious Diseases Lecture 4: C. difficile Dr. Nancy McQueen & Dr. Edith Porter.
Monday AM report
Diarrhea A child with diarrhea.
Inflammatory Bowel Disease
Clostridium difficile Infection (CDI): Increasingly Severe and Rapidly Fatal Disease Requires High Certainty of Treatment Efficacy Dale N. Gerding, MD.
Big Bad Bugs in the Dialysis Unit Douglas Shemin, MD Kidney Diseases and Hypertension Division, Rhode Island Hospital.
Clostridium difficile Prevention and Treatment Katrina Beining & Christina Gardner Introduction Clostridium difficile (C. diff) is a gram-positive, spore-forming.
Clostridium difficile: Shifting Sands of a Pesky Pathogen
What’s All the Fuss About Clostridium difficile? Peter C. Iwen, PhD, D(ABMM) Nebraska Public Health Laboratory.
Raneen Omary. Contents Definition Pathogenesis Epidemiology Acute Radiation Enteritis Chronic Radiation Enteritis Risk Factors Diagnosis DD Medical Management.
Outline C. difficile infection Fecal microbiota
Preventing and Treating C.difficile Lisa Casey, M.D. Assistant Professor, UT Southwestern Medical Center TSGE / SGNA Annual Scientific Meeting September.
Infectious Diarrheas - Overview Greatest cause of morbidity and mortality worldwide Scope of disease: 1993, E.coli 0157:H Cyclospora 1998.
Clostridium perfringens The agent of - Gangrene - Food poisoning Bacteria features: GPB, Capsulate, non-motile. Spores: bulging Rapidly growing (doubling.
Case Presentation Thamer Abdullah Bin Traiki. Case Presentation A 44-year-old woman with a history of multiple complicated urinary tract infections requiring.
Crohn’s Disease & Mycobacterial Infections Kimberly Persley, MD October 19, 2005.
Clostridium difficile
Clostridium difficile Separating key facts from fiction S P Borriello
Clostridium Difficile BY: KELSEY COMBS AND ROSA CORDOVA.
Lec. No. 11 Dr. Manahil Clostridium difficile C. difficile is a gram positive, spore forming, obligate anaerobe. Colonies of the organism are about 4mm.
Giardiasis Giardia Enteritis Lambliasis Beaver Fever.
Date of download: 5/28/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Clinical algorithm for the approach to patients with community-acquired.
Klebsiella oxytoca as a Causative Organism of Antibiotic-Associated Hemorrhagic Colitis N Engl J Med 2006;355: N Engl J Med 2006;355:
R1 김동연 /prof. 이창균. Introduction  Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high.
Dept. of Infectious Diseases 杨绍基. Amebic dysentery Definition Parasitic disease, Entamoeba histolytica, trophozoites induce submucosal ulcerations abdominal.
Clostridium difficile infections
Clostridium difficile infection (CDI) 소화기내과 R4 신아리 1.
Don’t Let Your Sinus Infection Turn Into a Life Threatening Colon Infection.
© 2013 Pearson Education, Inc. Bell Ringer  What is an endospore, and what special characteristics do endospore forming bacteria have?
Complications in IBD for acute internal medicine S Sebastian.
<Review> Nosocomial Diarrhea:
Clostridium difficile Infection Fellow 이시내. Clostridium difficile  An anaerobic gram-positive, spore-forming, toxin-producing bacillus.  Transmitted.
A gastrointestinal problem
Approach to patients with Diarrhea
Treatment of Clostridium difficile Infection
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Oral Vancomycin as a Therapeutic Option for PSC
Management of Clostridium Difficile Infection
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Clostridium difficile
CLINICAL SOLVING PROBLEM
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
C. difficile Update Kim Vermedal, RN, MSN, CIC APIC January 25, 2019.
Current Threats to Public Health
Campylobacter Microbiology properties Curved (comma- or S-shaped)
Presentation transcript:

Clostridium difficile Ricardo A. Caicedo, M.D.

OBJECTIVES Introduction Epidemiology Clinical spectrum Diagnosis Treatment Prevention

INTRODUCTION Gram + bacillus Anaerobic Spore-forming Slow growing Difficult to culture Historically…. 1935: first described in fecal flora healthy neonates 1970s: toxins implicated in antibiotic-associated diarrhea and colitis JA Hobot University of Wales College of Medicine UK

FREQUENCY Age-dependent Neonates High colonization rate (60-65%) Usually asymptomatic carriers Infants (1-24 m) More symptomatic Peak: 6-12 m Children 3-18 y Prevalence 5-8% as in adults Outbreaks Nosocomial Daycare centers McFarland LV et al (2000). JPGN 31(3):

C. difficile in the neonate Susceptible to colonization Immature intestinal microflora Exposure to spores in the nursery Rarely symptomatic Immature mucosal inflammatory response Gut epithelial toxin receptor defect Maternal Ab Absence of complex dietary substrates

PATHOGENESIS Toxin-mediated Toxin A (enterotoxin) More biologically active Toxin B (cytotoxin) Diagnostic marker Toxins bind to villus enterocyte receptors Inflammation Increased permeability Increased secretion Fibrin deposition Activation of enteric NS Poutanen SM, Simor AE (2004) CMAJ 171(1):51-8. G

RISK FACTORS Disruption of normal microflora ANTIBIOTICS Altered mucin layer Prematurity Immunosuppression GI problems Short bowel Colonic stricture Hirschsprung’s IBD Co-infection

CLINICAL PRESENTATION Asymptomatic carrier Acute/protracted diarrhea Colitis Recurrent disease

Acute/protracted diarrhea > 3 watery stools/d for > 2 days Fluid content > 10 ml/kg/d Typical duration: 2-9 days Chronic diarrhea (>14 d) 7 wks-19 m (Cooperstock M, 1990) Other possible GI sx Colicky abdominal pain Abdominal distention Vomiting May or may not be associated with antibiotic use

Antibiotic-associated diarrhea 4-18 days after first antibiotic dose (Ferroni A et al, 1997) Almost any antimicrobial Abx exposure not prerequisite for C. diff. disease 78% symptomatic outpts had no abx for at least 1 m (Buenning DA et al, 1982) McFarland LV et al (2000). JPGN 31(3):

C. difficile COLITIS TYPES 1. Pseudomembranous 1. Pseudomembranous (PMC) 2. Non-PMC 3. Toxic megacolon SIGNS/Sx Profuse diarrhea Blood in stool Abdominal pain Crampy LQ tenderness Fever Leukocytosis/L shift

From G. Ginsberg MD, Univ. Penn. Pseudomembranous colitis Composition: Fibrin WBCs and cell debris Mucus AdherentRaised cm diameter

COMPLICATIONS Dehydration Protein-losing enteropathy Hypoalbuminemia Ascites/edema Colon perforation Shock (fulminant colitis) Undernutrition Recurrent infection

DIAGNOSIS Detection + clinical Detection of organism or its toxin is not diagnostic by itself If sx suggest C. diff. disease, but stool is negative, repeat stool assays Stool assays Gold standard = cytotoxin cell culture assay Drawback: results can take up to 72 h Culture on CCFA agar EIA (rapid enzyme immunoassay) Results within 24 h PPV 100% when both toxins A and B tested (Kader H et al, Gastro., 1998) Endoscopy – reserve for ill patients Pseudomembranes specific for C. diff. CT scan – less specific NEJM (1994) 330:256.

TREATMENT D/C inciting antibiotic if feasible Antibiotic therapy Metronidazole Vancomycin (PO) Bacitracin Biotherapeutics Probiotics Cholestyramine IVIG Whole bowel irrigation Avoid anti-motility agents

Treatment METRONIDAZOLE Pros: effective, less expensive Cons: taste, side effects, emerging resistance Dosing: mg/kg/d div. BID-QID VANCOMYCIN PO Pros: better colonic absorption, few side effects Cons: expensive, resistance, recurrence Indications: severe PMC, recurrence, immunocompromised Dosing: 40 mg/kg/d div. QID

Treatment PROBIOTICS LGG Saccharomyces boulardii N= 19 infants C. diff. + diarrhea PO yeast X 15 d, no abx Sx resolved in 95% within 1 wk Rectal infusion of stool from healthy donor Broth culture bacteria Cholestyramine Binds both C. diff. toxins Also binds vancomycin Tastes like sand/seawater Primary tx failure, but better at preventing relapse IVIG Successful in uncontrolled trials in adults Very limited data in children Colon irrigation N = 2 children (Liacouras C, Piccoli D, J Clin Gastro 1996) McFarland LV et al (2000). JPGN 31(3):

RECURRENCE 15-57% after standard tx Typically 2-8 wks after completion of tx Mechanisms Re-acquisition Persistence of spores in colon Resistant strains Management options PO Vanc Probiotics Cholestyramine IVIG Solution of fresh stool from healthy donor McFarland LV et al (2000). JPGN 31(3):

PREVENTION Exclusion from daycare for duration of diarrhea Avoid abx in 1 st 2 m after PMC Probiotics in pts with hx recurrent disease Inpatients Narrow spectrum and use of abx when possible Strict handwashing and enteric or contact precautions Alcohol based hand sanitizer is not sporicidal Decontaminate colonoscopes Sporicides = glutaraldehyde or sodium hypochlorite Brook I (2005). J Gastroenterol Hepatol. 20(2):182-6.

Rising rate and severity of C. difficile disease in U.S. Emergence of new strain Increased virulence Increased resistance Associated with use of fluoroquinolone antibiotics